Different mesoporous nanomaterials (MSNs) are constantly being developed for a range of
therapeutic purposes, but they invariably interact with blood components and may cause
hazardous side effects. Therefore, when designing and developing nanoparticles for
biomedical applications, hemocompatibility should be one of the primary goals to assess
their toxicity at the cellular level of all blood components. The aim of this study was to
evaluate the compatibility of human blood cells (erythrocytes, platelets, and leukocytes) after …